November #18 : Hit by a MAC Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

An Angel, A Ribbon, An Apple, A Cross

Four More Years!

A Dull Presidency

The Party's Over

Outside Looking In

Clinton & AIDS: A Report Card

Citizen Duane

Great Shape

Behind the Briefs

Butt (It) Itches

Drugs of Ill-Repute

In Defense of Sex

Babes in Boyland

A Treatment Named Desire

Jesse Helms Must Die

Does Dole Have AIDS?

Hit by a MAC Treatment

Energy Booster

Loads of Information



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

November 1996

Hit by a MAC Treatment

High-dose clarithromycin can kill

What you don't know can hurt you -- especially if you have a case of disseminated Mycobacterium avium complex (MAC) infection. If so, you'll want to take heed of this overdue warning from the National Institutes of Allergy and Infectious Diseases (NIAID): "Treatment of [MAC] patients with clarithromycin [the antibiotic with the trade name Biaxin] should not exceed the approved dose of 500 mg twice daily."

The reason? The third clinical trial in a row found that a dose of 1,000 mg twice daily, also used by some community physicians, killed PWAs. The part of the NIAID trial comparing higher to lower doses of clarithromycin (in combination with ethambutol and either rifabutin or clofazimine) was stopped prematurely by the government's Data and Safety Monitoring Board after the high-dose arm experienced to 70 percent more deaths -- 17 compared to 10.

Although the board's action occurred February 6, NIAID waited until July 23 to issue a national clinical alert to physicians. The agency explained that "following last week's International AIDS Conference [in Vancouver], we became aware of renewed concern among HIV-infected persons" about the dosing danger.

That concern was forcefully expressed in a protest by several ACT UP chapters during a conference presentation by the trial's coordinator. John Riley of ACT UP/New York explains, "It was shameful that NIAID did a study which unnecessarily put PWAs at risk, did not provide informed consent, led to predictable 'excess deaths' -- and then was covered up until we blew the whistle. What quiet criticism from NIAID's community advisory group failed to do for five months, our action accomplished in 10 minutes."




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    romanticseattle
    Tacoma
    Washington


    jimmy807
    San Antonio
    Texas


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.